WESTLAKE VILLAGE, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) announced today the
company has fully relocated its corporate headquarters to a 12,596-square-foot location in the Westlake Landmark office park in
Westlake Village, California.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/1aeeebe3-558d-4ff0-910f-74247bf8c712
MannKind, which is currently commercializing Afrezza® (insulin human) inhalation powder, moved from Valencia, California to be
in an area well known for its biopharmaceutical talent and to offer greater convenience to its current employees.
“MannKind is a dynamic, fast-moving and rapidly growing company. To fuel this growth, we need to add more talented people to our
team. Moving to Westlake Village, which is proximal to a large number of companies in our industry, will help us attract top
talent,” said Michael Castagna, CEO, MannKind Corporation. ”We’re excited to be a member of the Westlake Village and greater Conejo
Valley business community.”
MannKind has shattered the paradigm of diabetes management with Afrezza, the only inhalable insulin that improves glycemic
control in adults with diabetes. MannKind also has additional therapeutic products in the pipeline using its dry powder formulation
as a drug delivery platform.
About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the development and commercialization of inhaled therapeutic products
for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza®
(insulin human) inhalation powder, the Company’s first FDA approved product, in the United States, where it is available by
prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art
manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S.
For further information, visit www.mannkindcorp.com.
Company Contact: Rose Alinaya SVP, Investor Relations 818-661-5000 ir@mannkindcorp.com
